Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation

Bone Marrow Transplantation volume 53, pages 683–691 (2018)Cite this article

Subjects

Abstract

Acute myeloid leukemia with inv(3)(q21;q26.2)/t(3;3)(q21;q26.2) (3q26 AML) is a rare disease with poor prognosis and median survival of <1 year. To evaluate allogeneic stem cell transplantation (alloHSCT) in the treatment of 3q26 AML, we studied 98 patients reported to the European Society for Blood and Marrow Transplantation between 1995 and 2013. Majority of patients were transplanted using peripheral blood, from unrelated donors and after myeloablative conditioning. Fifty-three patients were transplanted with active disease and 45 in complete remission. After a median follow-up of 47 months, 2 year leukemia-free survival (LFS), overall survival (OS), relapse incidence (RI), non-relapse mortality (NRM), and graft-versus-host disease-free, relapse-free survival (GRFS) probabilities were 20%, 26%, 64%, 16%, and 14%, respectively. Two-year LFS and OS probabilities for patients transplanted in CR vs. those transplanted in active disease were 23.8 vs. 17% (p = NS) and 34.9 vs. 18.9% (p = NS), respectively. In multivariate analysis CR was the only factor associated with a trend for better LFS (p = 0.05, HR 0.64) and OS (p = 0.06, HR 0.65). CR also significantly influenced GRFS (p = 0.01; HR 0.55) and NRM (p = 0.02; HR 0.27). The results suggest that a proportion of patients might benefit from the procedure, especially if performed in CR.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

Similar content being viewed by others

References

  1. Swerdlow SH, Campo E, Harris NL, Jaffe SJ, Pileri SA, Stein H, et al. (editors). WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008.

    Google Scholar 

  2. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision of the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.

    Article  CAS  Google Scholar 

  3. Sun J, Konoplev SN, Wang X, Cui W, Chen SS, Medeiros LJ, et al. De novo acute myeloid leukemia with inv(3)(q21; q26.2) or t(3;3)(q21;q26.2): a clinicopathologic and cytogenetic study of an entity recently added to the WHO classification. Mod Pathol. 2011;24:384–9.

    Article  CAS  Google Scholar 

  4. Medeiros BC, Kohrt HE, Arber DA, Bangs CD, Cherry AM, Majeti R, et al. Immunophenotypic featutes of acute myeloid leukemia with inv(3)(q21; q26.2)/t(3;3)(q21;q26.2). Leuk Res. 2010;34:594–7.

    Article  CAS  Google Scholar 

  5. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–74.

    Article  Google Scholar 

  6. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council Trials. Blood. 2010;116:354–65.

    Article  CAS  Google Scholar 

  7. Lugthart S, Gröschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL, et al. Clinical, molecular and prognostic significance of WHO type inv(3)(q21; q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol. 2010;28:3890–8.

    Article  Google Scholar 

  8. Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325–36.

    Article  CAS  Google Scholar 

  9. Hospital MA, Thomas X, Castaigne S, Raffoux E, Pautas C, Gardin C, et al. Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML. Bone Marrow Transplant. 2012;47:1436–41.

    Article  CAS  Google Scholar 

  10. Ferguson P, Hills RK, Grech A, Betterige S, Kjeldsen L, Dennis M, et al. An operational definition of primary refractory acute myeloid leukaemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation. Haematologica. 2016;101:1351–8.

    Article  CAS  Google Scholar 

  11. Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP–EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 2016;51:610–1.

    Article  CAS  Google Scholar 

  12. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304.

    Article  CAS  Google Scholar 

  13. Poiré X, Labopin M, Maertens J, Yakoub-Agha I, Blaise D, Ifrah N, et al. Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). J Hematol Oncol. 2017;18:10–20.

    Google Scholar 

  14. Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I, et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant. 2005;11:108–14.

    Article  Google Scholar 

  15. Wanquet A, Prebet T, Berthon C, Sebert M, Roux C, Kulasekararaj A, et al. Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities. Am J Hematol. 2015;90:859–63.

    Article  CAS  Google Scholar 

  16. Gröschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BAM, Erpelinck C, et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell. 2014;157:369–81.

    Article  Google Scholar 

  17. Yamazaki H, Suzuki M, Otsuki A, Shimizu R, Bresnick EH, Engel JD, et al. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21; q26) by activating EVI1 expression. Cancer Cell. 2014;25:415–27.

    Article  CAS  Google Scholar 

  18. Lovén J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013;153:320–34.

    Article  Google Scholar 

  19. Zahler S, Bhatia M, Ricci A, Roy S, Morris E, Harrison L, et al. A phase I study of reduced-intensity conditioning and allogeneic stem cell transplantation followed by dose escalation of targeted consolidation immunotherapy with gemtuzumab ozogamycin in children and adolescents with CD33+ acute myeloid leukemia. Biol Blood Marrow Transplant. 2016;22:698–704.

    Article  CAS  Google Scholar 

  20. Terwey TH, Vega-Ruiz A, Hemmati PG, Martus P, Dietz E, le Coutre P, et al. NIH-defined graft-versus-host disease after reduced or myeloablative conditioning in patients with acute myeloid leukemia. Leukemia. 2012;26:536–42.

    Article  CAS  Google Scholar 

  21. Weisdorf D, Zhang MJ, Arora M, Horowitz MM, Rizzo JD, Eapen M. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. Biol Blood Marrow Transplant. 2012;18:1727–33.

    Article  Google Scholar 

  22. Ruggeri A, Battipaglia G, Labopin M, Ehninger G, Beelen D, Tischer J. et al. Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study. J Hematol Oncol. 2016;9:89

    Article  Google Scholar 

  23. Tsirigotis P, Byrne M, Schmid C, Baron F, Ciceri F, Esteve J, et al. Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. Bone Marrow Transplant. 2016;51:1431–8.

    Article  CAS  Google Scholar 

  24. Savani BN, Labopin M, Blaise D, Niederwieser D, Ciceri F, Ganser A, et al. Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT. Haematologica. 2016;101:256–62.

    Article  CAS  Google Scholar 

  25. Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and Myelodysplastic syndromes. J Clin Oncol. 2017;35:1154–61.

    Article  Google Scholar 

  26. Poiré X, Labopin M, Cornelissen JJ, Volin L, Richard Espiga C, Veelken JH, et al. Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: a study from the Acute Leukemia Working Party (ALWP) of the European Group of Blood and Marrow Transplantation (EBMT). Am J Hematol. 2015;90:719–24.

    Article  Google Scholar 

  27. Pasquini MC, Zhang M-J, Medeiros BC, Armand P, Hu ZH, Nishihori T, et al. Hematopoietic cell transplantation outcomes in monosomal karyotype myeloid malignancies. Biol Blood Marrow Transplant. 2016;22:248–57.

    Article  Google Scholar 

  28. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352:1087–92.

    Article  CAS  Google Scholar 

  29. Rogers HJ, Vardiman JW, Anastasi J, Raca G, Savage NM, Cherry AM, et al. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21; q26.6)/t(3;3)(q21;q26.6): A Bone Marrow Pathology Group study. Haematologica. 2014;99:821–8.

    Article  Google Scholar 

Download references

Acknowledgements

The authors would like to thank all EBMT centers for their contribution and additional data reporting.

Author information

Author notes

  1. These authors contributed equally: Kazimierz Halaburda, Arnon Nagler.

Authors and Affiliations

  1. Department of Stem Cell Transplantation, Institute of Haematology and Transfusion Medicine, Warsaw, Poland

    Kazimierz Halaburda

  2. EBMT Paris Study Office/CEREST-TC, Paris, France

    Myriam Labopin, Mohamed Houhou & Mohamad Mohty

  3. Department of Haematology, Saint Antoine Hospital, Paris, France

    Myriam Labopin, Mohamed Houhou & Mohamad Mohty

  4. INSERM UMR 938, Paris, France

    Myriam Labopin, Mohamed Houhou & Mohamad Mohty

  5. Université Pierre et Marie Curie, Paris, France

    Myriam Labopin, Mohamed Houhou & Mohamad Mohty

  6. Division of Hematology, Oncology and Hemostasiology, University Hospital Leipzig, Leipzig, Germany

    Dietger Niederwieser

  7. Department of Medicine-Hematology, Oncology, University of Freiburg, Freiburg, Germany

    Jürgen Finke

  8. Stem Cell Transplantation Unit, HUCH Comprehensive Cancer Center, Helsinki, Finland

    Liisa Volin

  9. Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium

    Johan Maertens

  10. Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands

    Jan J. Cornelissen

  11. CHU Bordeaux, Hôpital Haut-Leveque, Pessac, France

    Noel Milpied

  12. KMT Zentrum, Deutsche Klinik für Diagnostik, Wiesbaden, Germany

    Gernot Stuhler

  13. Department of Stem Cell Transplantation, University Hospital Eppendorf, Hamburg, Germany

    Nicolaus Kröger

  14. Hospital Clinic, Department of Hematology, IDIBAPS, Barcelona, Spain

    Jordi Esteve

  15. Chaim Sheba Medical Center, Tel-Hashomer, EBMT Paris Study Office, Israel, France

    Arnon Nagler

Authors
  1. Kazimierz Halaburda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Myriam Labopin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohamed Houhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dietger Niederwieser
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jürgen Finke
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Liisa Volin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Johan Maertens
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jan J. Cornelissen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Noel Milpied
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Gernot Stuhler
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Nicolaus Kröger
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jordi Esteve
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Mohamad Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Arnon Nagler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kazimierz Halaburda.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Halaburda, K., Labopin, M., Houhou, M. et al. AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation. Bone Marrow Transplant 53, 683–691 (2018). https://doi.org/10.1038/s41409-018-0165-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-018-0165-x

Search

Advanced search

Quick links